TITLE

Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival

AUTHOR(S)
Allendorf, John D.; Lauerman, Margaret; Bill, Aliye; DiGiorgi, Mary; Goetz, Nicole; Vakiani, Efsevia; Remotti, Helen; Schrope, Beth; Sherman, William; Hall, Michael; Fine, Robert L.; Chabot, John A.
PUB. DATE
January 2008
SOURCE
Journal of Gastrointestinal Surgery;Jan2008, Vol. 12 Issue 1, p91
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Background: We evaluated the feasibility and efficacy of neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic cancer.Materials and Methods: From October 2000 to August 2006, 245 patients with pancreatic adenocarcinoma underwent surgical exploration at our institution. Of these, 78 patients (32%) had undergone neoadjuvant therapy for initially unresectable disease, whereas the remaining patients (serving as the control group) were explored at presentation (n=167). All neoadjuvant patients received gemcitabine-based chemotherapy, often in conjunction with docetaxal and capecitabine in a regimen called GTX (81%). Seventy-five percent of neoadjuvant patients also received preoperative abdominal radiation (5,040 rad).Results: Neoadjuvant patients were younger than control-group patients (60.8 vs 66.2 years, respectively, p<0.002). Seventy-six percent of neoadjuvant patients were resected as compared to 83% of control patients (NS). Concomitant vascular resection was required in 76% of neoadjuvant patients but only 20% of NS (p<0.01). Complications were more frequent in the neoadjuvant group (44.1 vs 30.9%, p<0.05), and mortality was higher (10.2 vs 2.9%, p<0.03). Among the neoadjuvant patients, all but one of the deaths were in patients that underwent arterial reconstruction. Mortality for patients undergoing a standard pancreatectomy without vascular resection was 0.8% in this series. Of patients resected, negative margins were achieved in 84.7% of neoadjuvant patients and 72.7% of NS. Within the cohort of neoadjuvant patients, radiation significantly increased the complication rate (13.3 vs 54.6%, p<0.006), but did not affect median survival (512 vs 729 days, NS). Median survival for patients who received neoadjuvant therapy (503 days) was longer than NS that were found to be unresectable at surgery (192 days, p<0.001) and equivalent to NS that were resected (498 days).Conclusions: Resection rate, margin status, and median survivals were equivalent when neoadjuvant patients were compared to patients considered resectable by traditional criteria, demonstrating equal efficacy. Surgical resection with venous reconstruction following neoadjuvant therapy for patients with locally advanced pancreatic cancer can be performed with acceptable morbidity and mortality. This approach extended the boundaries of surgical resection and greatly increased median survival for the "inoperable" patient with advanced pancreatic cancer.
ACCESSION #
29368992

 

Related Articles

  • Isolated pancreatic metastasis from rectal cancer: a case report and review of literature. Chao-Wei Lee; Ren-Chin Wu; Jun-Te Hsu; Chun-Nan Yeh; Ta-Sen Yeh; Tsann-Long Hwang; Yi-Yin Jan; Miin-Fu Chen // World Journal of Surgical Oncology;2010, Vol. 8, p26 

    Isolated pancreatic metastases from a non-pancreatic primary malignancy are very rare. Studies have shown that resection of metastases is of proven benefit in some types of tumors. We report a case of 76-year-old Taiwanese woman with rectal adenocarcinoma treated with neoadjuvant...

  • Evidence-Based Guidelines for Adjuvant Therapy for Resected Adenocarcinoma of the Pancreas. Iott, Matthew J.; Corsini, Michele M.; Miller, Robert C. // Clinical Journal of Oncology Nursing;Aug2008, Vol. 12 Issue 4, p599 

    Pancreatic cancer, the fourth most common cause of cancer deaths, has a five-year survival rate of 5% or less. Surgical removal of the tumor may improve survival, but survival remains poor even in optimally resected patients. The best adjuvant therapy for patients with resected pancreatic cancer...

  • O-0003P-ERK, P-AKT AND P53 AS TISSUE BIOMARKERS IN ERLOTINIB-TREATED PATIENTS WITH ADVANCED PANCREATIC CANCER: A TRANSLATIONAL SUBGROUP ANALYSIS FROM AIO-PK0104. Boeck, Stefan; Siveke, Jens; Ormanns, Steffen; Laubender, Ruediger; Jung, Andreas; Haas, Michael; Vehling-Kaiser, Ursula; Winkelmann, Cornelia; von Weikersthal, Ludwig Fischer; Clemens, Michael; Gauler, Thomas; Märten, Angela; Klein, Stefan; Kojouharoff, Georgi; Geissler, Michael; Greten, Tim; Kirchner, Thomas; Heinemann, Volker // Annals of Oncology;Jun2013, Vol. 24 Issue suppl_4, piv12 

    No abstract available.

  • The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Brunner, Thomas B.; Scott-Brown, Martin // Radiation Oncology;2010, Vol. 5, p64 

    Pancreatic ductal carcinoma is one of the most lethal malignancies, but in recent years a number of positive developments have occurred in the management of pancreatic carcinoma. This article aims to give an overview of the current knowledge regarding the role of radiotherapy in the treatment of...

  • Surgical resection versus palliative chemoradiotherapy for the management of pancreatic cancer with local venous invasion: a decision analysis. Abramson, Michael A.; Swanson, Edward W.; Whang, Edward E. // Journal of Gastrointestinal Surgery;Jan2009, Vol. 13 Issue 1, p26 

    Background: Benefit from pancreaticoduodenectomy (PD) combined with superior mesenteric-portal vein (SMV-PV) resection in the management of pancreatic adenocarcinoma with local venous invasion remains controversial.Methods: Using formal decision analysis, we compared...

  • Treatment of locoregional disease: adjuvant versus neoadjuvant. Heinemann, V. // Annals of Oncology;Sep2012 Supplement 10, Vol. 23 Issue suppl_10, px141 

    The efficacy of adjuvant therapy after the resection of pancreatic adenocarcinoma has been demonstrated by several randomized studies. Postoperative treatment applied either as chemotherapy alone or in combination with chemoradiotherapy is therefore considered a recommended standard in...

  • Therapeutic advances in non-small cell lung cancer. Valliéres, Eric; Peters, Solange; Van Houtte, Paul; Dalal, Paras; Lim, Eric // Thorax;Dec2012, Vol. 67 Issue 12, p1097 

    Despite decades of research, therapeutic advances in non-small cell lung cancer (NSCLC) have progressed at a painstaking slow rate with few improvements in standard surgical resection for early stage disease and chemotherapy or radiotherapy for patients with advanced disease. In the past 18...

  • Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer. Igarashi, Hisato; Ito, Tetsuhide; Kawabe, Ken; Hisano, Terumasa; Arita, Yoshiyuki; Kaku, Toyoma; Takayanagi, Ryoichi; Zenilman, Michael E. // World Journal of Gastroenterology;9/14/2008, Vol. 14 Issue 34, p5311 

    AIM: To evaluate the chemoradiotherapy for locally advanced pancreatic cancer utilizing low dose gemcitabine as a radiation sensitizer administered twice weekly. METHODS: We performed a retrospective analysis of chemoradiotherapy utilizing gemcitabine administered twice weekly at a dose of 40...

  • Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. Sho, Masayuki; Akahori, Takahiro; Tanaka, Toshihiro; Kinoshita, Shoichi; Tamamoto, Tetsuro; Nomi, Takeo; Yamato, Ichiro; Hokuto, Daisuke; Yasuda, Satoshi; Kawaguchi, Chihiro; Nishiofuku, Hideyuki; Marugami, Nagaaki; Enomonoto, Yasunori; Kasai, Takahiko; Hasegawa, Masatoshi; Kichikawa, Kimihiko; Nakajima, Yoshiyuki // Journal of Hepato -- Biliary -- Pancreatic Sciences;Feb2013, Vol. 20 Issue 2, p197 

    Background/purpose: The therapeutic options available as preoperative strategies for resectable pancreatic cancer have received worldwide attention. We have recently introduced neoadjuvant chemoradiotherapy (NACRT) to achieve local control and possibly complete cure. In this study, we have...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics